Pembrolizumab Clinical Trials
439 recruitingDrug
Phase 2260Phase 1147Phase 389Early Phase 17Not Applicable5Phase 43
Showing 1–20 of 439 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 1
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI)32 enrolled10 locationsNCT05673200
Recruiting
Phase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma
National Cancer Institute (NCI)255 enrolled108 locationsNCT07198074
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1149 locationsNCT04267848
Recruiting
Phase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled112 locationsNCT06524544
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled316 locationsNCT06096844
Recruiting
Phase 1Phase 2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Endometrial CancerEndometrial CarcinomaCancer of Endometrium+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06253494
Recruiting
Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled177 locationsNCT04671667
Recruiting
Phase 1
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794
Recruiting
Phase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled196 locationsNCT07061977
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled128 locationsNCT07061964
Recruiting
Phase 1
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)27 enrolled11 locationsNCT06439836
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled121 locationsNCT06770582
Recruiting
Phase 2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Merck Sharp & Dohme LLC1,023 enrolled81 locationsNCT07216703
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 3
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled196 locationsNCT07195695
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled346 locationsNCT06875310
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled836 locationsNCT05812807